[go: up one dir, main page]

PT1725569E - Pró-fármacos de piperazina e agentes antivirais de piperidina substituída - Google Patents

Pró-fármacos de piperazina e agentes antivirais de piperidina substituída Download PDF

Info

Publication number
PT1725569E
PT1725569E PT05724510T PT05724510T PT1725569E PT 1725569 E PT1725569 E PT 1725569E PT 05724510 T PT05724510 T PT 05724510T PT 05724510 T PT05724510 T PT 05724510T PT 1725569 E PT1725569 E PT 1725569E
Authority
PT
Portugal
Prior art keywords
prodrugs
piperazine
antiviral agents
substituted piperidine
piperidine antiviral
Prior art date
Application number
PT05724510T
Other languages
English (en)
Inventor
Yasutsugu Ueda
John F Kadow
Kap-Sun Yeung
Nicholas A Meanwell
Zhongxing Zhang
Timothy P Connolly
Tao Wang
Chung-Pin H Chen
David Kenneth Leahy
Shawn K Pack
Nachimuthu Soundararajan
Pierre Sirard
Kathia Levesque
Dominique Thoraval
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1725569(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT1725569E publication Critical patent/PT1725569E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/062Organo-phosphoranes without P-C bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT05724510T 2004-03-15 2005-03-03 Pró-fármacos de piperazina e agentes antivirais de piperidina substituída PT1725569E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55332004P 2004-03-15 2004-03-15
US63523104P 2004-12-10 2004-12-10

Publications (1)

Publication Number Publication Date
PT1725569E true PT1725569E (pt) 2008-03-28

Family

ID=34963934

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05724510T PT1725569E (pt) 2004-03-15 2005-03-03 Pró-fármacos de piperazina e agentes antivirais de piperidina substituída

Country Status (26)

Country Link
US (12) US7745625B2 (pt)
EP (1) EP1725569B1 (pt)
JP (1) JP4734318B2 (pt)
KR (1) KR101153594B1 (pt)
CN (1) CN101941990B (pt)
AR (1) AR048039A1 (pt)
AT (1) ATE384728T1 (pt)
AU (1) AU2005223736C1 (pt)
BR (1) BRPI0508876B8 (pt)
CA (1) CA2560253C (pt)
CY (1) CY1107419T1 (pt)
DE (1) DE602005004517T2 (pt)
DK (1) DK1725569T3 (pt)
ES (1) ES2299022T3 (pt)
GE (1) GEP20094736B (pt)
HR (1) HRP20080064T5 (pt)
IL (1) IL211961A (pt)
MY (1) MY139243A (pt)
NO (1) NO336742B1 (pt)
NZ (2) NZ585294A (pt)
PE (1) PE20051151A1 (pt)
PL (1) PL1725569T3 (pt)
PT (1) PT1725569E (pt)
RS (1) RS50567B (pt)
TW (1) TWI344843B (pt)
WO (1) WO2005090367A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
JP5433690B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー 抗−hiv薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン
PL2323633T3 (pl) * 2008-09-04 2012-08-31 Viiv Healthcare Uk No 4 Ltd Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
US8435562B2 (en) * 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
JP5752789B2 (ja) 2010-06-04 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
CN103339141B (zh) 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
WO2012106189A1 (en) * 2011-01-31 2012-08-09 Bristol-Myers Squibb Company Methods of making hiv attachment inhibitor prodrug compound and intermediates
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
CA2849475A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
US20140356863A1 (en) 2011-11-21 2014-12-04 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CA2864087A1 (en) 2012-02-08 2013-08-15 Bristol-Myers Squibb Company Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
HRP20190980T1 (hr) 2012-06-19 2019-08-23 Debiopharm International Sa Derivati predlijeka (e)-n-metil-n((3-metilbenzofuran-2 il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
US20140221361A1 (en) 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
WO2014130810A1 (en) 2013-02-25 2014-08-28 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
CN105229006A (zh) * 2013-03-27 2016-01-06 百时美施贵宝公司 作为hiv吸附抑制剂的哌嗪和高哌嗪衍生物
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
AU2015243500B2 (en) 2014-04-11 2017-03-30 ViiV Healthcare UK (No.4) Limited Triterpenoids with HIV maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
CA2967679A1 (en) 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CA2971104A1 (en) 2014-12-18 2016-06-23 ViiV Healthcare UK (No.4) Limited A process for preparing halogenated azaindole compounds using boroxine
WO2016100651A1 (en) 2014-12-18 2016-06-23 Bristol-Myers Squibb Company A process for preparing halogenated azaindole compounds using pybrop
US20180094019A1 (en) 2015-04-14 2018-04-05 ViiV Healthcare UK (No.4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity
LT3355884T (lt) 2015-10-01 2021-07-26 Olema Pharmaceuticals, Inc. Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai
ES2873510T3 (es) * 2015-12-14 2021-11-03 Max Planck Gesellschaft Derivados solubles en agua de compuestos de 3,5-difenil-diazol
US20190030025A1 (en) 2016-02-04 2019-01-31 VIIV Healthcare UK (No.5) Limited Fostemsavir for use in heavily treatment-experienced hiv-1 infected individuals
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3419628B1 (en) 2016-02-26 2020-10-14 Debiopharm International SA Medicament for treatment of diabetic foot infections
HUE061885T2 (hu) 2017-11-21 2023-08-28 Pfizer 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója
JP7429236B2 (ja) 2019-01-17 2024-02-07 ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド ホステムサビルの調製方法
HUE062061T2 (hu) 2019-02-14 2023-09-28 Debiopharm Int Sa Afabicin készítmény, eljárás annak elõállítására
PH12021553086A1 (en) 2019-06-14 2023-08-14 Debiopharm Int Sa Medicament and use thereof for treating bacterial infections involving biofilm
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
IL313306A (en) 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
KR20250099718A (ko) 2022-11-02 2025-07-02 비브 헬스케어 유케이 (넘버5) 리미티드 항원 결합 단백질
WO2025229018A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025229019A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101017C (en) 1992-07-24 1999-10-26 Masahiko Higuma Ink jet cartridge, ink jet head and printer
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
ATE304853T1 (de) * 2000-07-10 2005-10-15 Bristol Myers Squibb Co Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin- derivaten
DK1363705T3 (da) * 2001-02-02 2012-09-24 Bristol Myers Squibb Co Sammensætning og antiviral aktivitet i substituerede azaindoloxoeddikesurpiperazin-derivater
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AU2003215469A1 (en) 2002-03-28 2003-10-13 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
WO2012106189A1 (en) * 2011-01-31 2012-08-09 Bristol-Myers Squibb Company Methods of making hiv attachment inhibitor prodrug compound and intermediates
CA2864087A1 (en) * 2012-02-08 2013-08-15 Bristol-Myers Squibb Company Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound

Also Published As

Publication number Publication date
IL211961A (en) 2013-08-29
EP1725569B1 (en) 2008-01-23
TWI344843B (en) 2011-07-11
US8168615B2 (en) 2012-05-01
US8871771B2 (en) 2014-10-28
RS50567B (sr) 2010-05-07
US20130253196A1 (en) 2013-09-26
CY1107419T1 (el) 2012-12-19
JP4734318B2 (ja) 2011-07-27
US20150025240A1 (en) 2015-01-22
CN101941990A (zh) 2011-01-12
RU2006136390A (ru) 2008-04-27
NO336742B1 (no) 2015-10-26
US20100210599A1 (en) 2010-08-19
KR20060129533A (ko) 2006-12-15
US20150232414A1 (en) 2015-08-20
GEP20094736B (en) 2009-07-27
DE602005004517T2 (de) 2009-01-22
NZ585294A (en) 2011-09-30
HRP20080064T5 (en) 2008-10-31
PL1725569T3 (pl) 2008-09-30
US20150315218A1 (en) 2015-11-05
CA2560253A1 (en) 2005-09-29
US20210023098A1 (en) 2021-01-28
TW200600096A (en) 2006-01-01
BRPI0508876B1 (pt) 2020-05-26
AU2005223736C1 (en) 2011-10-06
US8461333B2 (en) 2013-06-11
ATE384728T1 (de) 2008-02-15
KR101153594B1 (ko) 2012-07-05
US20180000849A1 (en) 2018-01-04
US11369624B2 (en) 2022-06-28
US20050209246A1 (en) 2005-09-22
AU2005223736B2 (en) 2011-05-26
DE602005004517D1 (de) 2008-03-13
RU2374256C2 (ru) 2009-11-27
HK1148533A1 (en) 2011-09-09
CN101941990B (zh) 2012-04-25
WO2005090367A1 (en) 2005-09-29
BRPI0508876B8 (pt) 2021-05-25
CA2560253C (en) 2013-01-15
HRP20080064T3 (hr) 2008-03-31
JP2007529519A (ja) 2007-10-25
NZ549867A (en) 2010-07-30
DK1725569T3 (da) 2008-06-02
US20160361328A1 (en) 2016-12-15
MY139243A (en) 2009-09-30
AR048039A1 (es) 2006-03-22
NO20064062L (no) 2006-12-08
AU2005223736A1 (en) 2005-09-29
US20120238755A1 (en) 2012-09-20
EP1725569A1 (en) 2006-11-29
US20190111066A1 (en) 2019-04-18
PE20051151A1 (es) 2006-01-20
BRPI0508876A (pt) 2007-09-04
US20200046743A1 (en) 2020-02-13
US7745625B2 (en) 2010-06-29
HK1096687A1 (en) 2007-06-08
ES2299022T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
PT1725569E (pt) Pró-fármacos de piperazina e agentes antivirais de piperidina substituída
IL194540A0 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
AP2006003768A0 (en) TetraazabenzoÄeÜazulene derivatives and analogs tehereof
SI1802579T1 (sl) Derivati 3-arilaminopiridina
ZA200800256B (en) Antiviral compounds and methods
IL211894A0 (en) Amide derivatives
PL1648874T3 (pl) Pochodne piperazyny i ich zastosowanie jako środków leczniczych
IL181433A0 (en) Pyrimidine derivatives
IL181609A0 (en) Combination comprising zd6474 and imatinib
IL183216A0 (en) Nepetalactams and n-substituted derivatives thereof
IL181386A0 (en) Pyrimidine derivatives
IL183657A0 (en) Amide derivatives
PT1727809E (pt) Derivados de morfolina e tiomorfolina substituídas
IL183293A0 (en) Malonamide derivatives
PT1771421E (pt) Derivados de n-hidroxiamida e sua utilização
GB0415367D0 (en) Pyrimidine derivatives
IL179914A0 (en) Pyrimidine derivatives
IL176922A0 (en) Compositions and methods of use of a-type procyanidins
IL176426A0 (en) Di-steroidal prodrugs of estradiol
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
ZA200607466B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
IL177945A0 (en) Prodrugs of piperazine and substituted piperidine antiviral agents
SI1725569T1 (sl) Predzdravila piperazinskih in substituiranih piperidinskih protivirusnih sredstev
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
ZA200702227B (en) Combination comprising ZD6474 and imatinib